Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Curious about what you can buy with credit card points? Explore a variety of exciting options to make the most of your rewards!
28,188 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Taiwan Semiconductor's dominant foundry role continues shaping AI chip supply. This deep dive explains why taiwan sem...
Anthropic faces a high-stakes clash with the Pentagon while preparing for a potential IPO. The CFO's strategy will be...
A focused look at OmniAb's Q4 2025 earnings and what the numbers could mean for investors. Discover the drivers, risk...
A caller in his 60s with a six-figure income and no retirement savings since 2008 receives a blunt reality check on T...
Celanese (CE) stands at an inflection point as 2026 begins. This article breaks down the potential drivers behind cel...
A viral post about a person earning $36k a year with $136k in debt and a prize horse has lawmakers and financiers wei...
A growing number of retirees are deploying a blended 6.4% yield strategy, combining high-quality dividends with real ...
A prominent AI founder challenges the notion that automation alone boosts margins, revealing a doubled headcount desp...
Chipmakers led U.S. equities higher, helping the S&P 500 reach a new close. This piece breaks down what moved markets...
A common retirement move—selling a primary home with a large capital gain—can trigger higher Medicare premiums two ye...
With 2026 tax rules lifting the tax burden on retirees, advisers are turning to the three-bucket 401(K) withdrawal st...